Gilead Sciences, Inc. (NASDAQ:GILD) Insider Johanna Mercier Sells 3,000 Shares

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $333,090.00. Following the sale, the insider directly owned 117,168 shares of the company's stock, valued at approximately $13,009,163.04. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Johanna Mercier also recently made the following trade(s):

• On Tuesday, July 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $111.03, for a total transaction of $333,090.00.
• On Monday, June 16th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $110.17, for a total transaction of $330,510.00.
• On Thursday, May 22nd, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00.

Gilead Sciences Price Performance

Shares of GILD traded down $1.01 during mid-day trading on Thursday, reaching $108.84. The company had a trading volume of 1,957,875 shares, compared to its average volume of 7,660,046. The company's 50 day simple moving average is $108.37 and its 200 day simple moving average is $104.94. Gilead Sciences, Inc. has a 1-year low of $70.78 and a 1-year high of $119.96. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The company has a market capitalization of $135.39 billion, a price-to-earnings ratio of 22.97, a P/E/G ratio of 0.71 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same quarter last year, the business earned ($1.32) EPS. The firm's quarterly revenue was down .3% on a year-over-year basis. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were issued a dividend of $0.79 per share. The ex-dividend date was Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.90%. Gilead Sciences's payout ratio is 66.53%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Southland Equity Partners LLC lifted its position in shares of Gilead Sciences by 2.9% during the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company's stock valued at $364,000 after acquiring an additional 92 shares during the period. Redwood Financial Network Corp lifted its position in shares of Gilead Sciences by 4.0% during the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock valued at $234,000 after acquiring an additional 98 shares during the period. Twelve Points Wealth Management LLC lifted its position in shares of Gilead Sciences by 1.5% during the 2nd quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company's stock valued at $721,000 after acquiring an additional 98 shares during the period. Argentarii LLC lifted its position in shares of Gilead Sciences by 3.0% during the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock valued at $380,000 after acquiring an additional 99 shares during the period. Finally, Nicolet Advisory Services LLC lifted its position in shares of Gilead Sciences by 2.9% during the 4th quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock valued at $322,000 after acquiring an additional 100 shares during the period. Institutional investors own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on GILD shares. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Morgan Stanley lifted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Finally, Cantor Fitzgerald started coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price on the stock. Nine equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $111.38.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.